TABLE 1.
Subject baseline demographics
Data are presented as medians (minimum, maximum).
| Group and Cohort |
||||
|---|---|---|---|---|
| HCV |
NAFLD |
|||
| 280 mga | 560 mg | 280 mg | 560 mg | |
| Male/female (n) | 8/4 | 5/1 | 3/3 | 2/4 |
| White/black (n) | 10/2 | 4/2 | 6/0 | 6/0 |
| Age (years) | 50 (44, 59) | 51 (43, 54) | 51 (28, 58) | 48 (28, 52) |
| Weight (kg) | 92 (67, 99) | 104 (86, 123) | 104 (79, 150) | 101 (78, 143) |
| BMI (kg/m2) | 28 (25, 42) | 33 (26, 41) | 38 (27, 42) | 38 (27, 43) |
| Total bilirubin (mg/dl) | 0.8 (0.3, 1.0) | 0.6 (0.3, 1.4) | 0.6 (0.3, 1.1) | 0.5 (0.3, 2.6) |
| ALT (U/l) | 95 (58, 288) | 113 (81, 214) | 99 (52, 322) | 104 (77, 115) |
| AST (U/l) | 64 (43, 271) | 89 (46, 110) | 60 (38, 325) | 66 (54, 104) |
| Platelets (cells/mm3) | 208 (177, 327) | 192 (150, 225) | 275 (157, 341) | 282 (162, 319) |
BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
a
Two cohorts of six subjects were used to study single and multiple dose pharmacokinetics.